The pharmacotherapy of male hypogonadism besides androgens
The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Adulthood male hypogonadism (HG) is the most common form of HG. Although testosterone (T) replacement therapy (TRT) is the most common way of treating HG, other options are available depending on patient's needs and expectations. AREAS COVERED: We analyze alternative options to TRT as a medical intervention in treating HG. Gonadotropin (Gn) therapy is the treatment of choice in men with secondary HG (sHG), who require fertility. Gonadotropin-releasing hormone therapy represents an alternative to Gn for inducing spermatogenesis in patients with sHG, however, its use is limited by the poor patient compliance and high cost. In obese HG men, lifestyle modifications and, in particular, weight loss should be the first step. Recent data suggest that antiestrogens represent a successful treatment for sHG. Other potential therapeutic options include the stimulation of hypothalamic activity (i.e., kisspeptin and neurokinin-B agonists). Conversely, the possibility of increasing Leydig cell steroid production, independently from Gn stimulation, seems unreliable. EXPERT OPINION: Understanding the nature of male HG and patient's needs are mandatory before choosing among treatment options. For primary HG only TRT is advisable, whereas for the secondary form several alternative possibilities can be offered.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011 · cited 1×
“Several studies have demonstrated that, in individuals at risk, intensive lifestyle intervention, along with nutritional counseling and physical activity is able to reduce weight loss and insulin resistance, preventing the progression to overt diabetes [132-137].”
BackgroundTuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873 · cited 1×
“Several studies have demonstrated that, in individuals at risk, intensive lifestyle intervention, along with nutritional counseling and physical activity is able to reduce weight loss and insulin resistance, preventing the progression to overt diabetes [132-137].”
BackgroundNathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Bhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2354 · Cited by 1,954
Identification of late-onset hypogonadism in middle-aged and elderly men
Wu, F. C. W., Tajar, A., Beynon, J. M., Pye, S. R., Silman, A. J., Finn, J. D., O'Neill, T. W., Bartfai, G., Casanueva, F. F., Forti, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0911101 · Cited by 1,544 · cited 2×
“[28] introduced a new definition of LOH.”
BackgroundReduction in Weight and Cardiovascular Disease Risk Factors in Individuals With Type 2 Diabetes
The Look AHEAD Research Group (2007) · Diabetes Care · doi:10.2337/dc07-0048 · Cited by 1,522
Gillies, C. L., Abrams, K. R., Lambert, P. C., Cooper, N. J., Sutton, A. J., Hsu, R. T., & Khunti, K. (2007) · BMJ · doi:10.1136/bmj.39063.689375.55 · Cited by 1,171 · cited 1×
“Several studies have demonstrated that, in individuals at risk, intensive lifestyle intervention, along with nutritional counseling and physical activity is able to reduce weight loss and insulin resistance, preventing the progression to overt diabetes [132-137].”
BackgroundRole of steroidogenic acute regulatory protein in adrenal and gonadal steroidogenesis
Lin, D., Sugawara, T., Strauss, J. F., Clark, B. J., Stocco, D. M., Saenger, P., Rogol, A., & Miller, W. L. (1995) · Science · doi:10.1126/science.7892608 · Cited by 1,030 · cited 1×
“In humans, StAR mutations cause lipoid congenital adrenal hyperplasia that ranges from an almost complete inability to synthesize steroids [10], to less severe forms that retain partial StAR protein activity [11].”
BackgroundEffect of Lifestyle Changes on Erectile Dysfunction in Obese Men: A Randomized Controlled Trial
Esposito, K., Giugliano, F., Di Palo, C., Giugliano, G., Marfella, R., D'Andrea, F., D'Armiento, M., & Giugliano, D. (2004) · JAMA · doi:10.1001/jama.291.24.2978 · Cited by 841 · cited 1×
“Similarly, weight loss per se [138], along with lifestyle modifications, is able to improve sexual function, although only limited data have been published so far [138,139].”
BackgroundThe Look AHEAD Research Group (2003) · Controlled Clinical Trials · doi:10.1016/s0197-2456(03)00064-3 · Cited by 767
Bariatric Surgery Worldwide 2003
Buchwald, H., & Williams, S. E. (2004) · Obesity Surgery · doi:10.1381/0960892042387057 · Cited by 731
Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males
Dhillo, W. S., Chaudhri, O. B., Patterson, M., Thompson, E. L., Murphy, K. G., Badman, M. K., McGowan, B. M., Amber, V., Patel, S., Ghatei, M. A., et al. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1468 · Cited by 656
Enigma of the peripheral benzodiazepine receptor
Gavish, M., Bachman, I., Shoukrun, R., Katz, Y., Veenman, L., Weisinger, G., & Weizman, A. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01424-8 · Cited by 512 · cited 1×
“The 18-kDa translocator protein (TSPO) [12], previously known as the peripheral-type benzodiazepine (BZD) receptor (PBR) -- a pharmacologically distinct and unrelated g-aminobutyric acid (GABA)-associated BZD binding site [13] -- is also expressed predominantly in mitochondria from steroid synthesizing cells, where it…”
BackgroundCorona, G., Rastrelli, G., Monami, M., Saad, F., Luconi, M., Lucchese, M., Facchiano, E., Sforza, A., Forti, G., Mannucci, E., et al. (2013) · European Journal of Endocrinology · doi:10.1530/eje-12-0955 · Cited by 414
Self-citationLacapère, J.-J., & Papadopoulos, V. (2003) · Steroids · doi:10.1016/s0039-128x(03)00101-6 · Cited by 342
Gupta, B. P. (2011) · Archives of Internal Medicine · doi:10.1001/archinternmed.2011.440 · Cited by 312 · cited 1×
“Similarly, weight loss per se [138], along with lifestyle modifications, is able to improve sexual function, although only limited data have been published so far [138,139].”
BackgroundTestosterone supplementation and sexual function: A meta-analysis study
Corona, G., Isidori, A. M., Buvat, J., Aversa, A., Rastrelli, G., Hackett, G., Rochira, V., Sforza, A., Lenzi, A., Mannucci, E., et al. (2014) · The Journal of Sexual Medicine · doi:10.1111/jsm.12536 · Cited by 263 · cited 1×
“In addition, the possible role of TRT in improving PDE5i outcomes [112] confirms the limited power of these classes of drugs in improving T levels.”
BackgroundSelf-citationNavarro, V. M., Gottsch, M. L., Wu, M., García-Galiano, D., Hobbs, S. J., Bosch, M. A., Pinilla, L., Clifton, D. K., Dearth, A., Ronnekleiv, O. K., et al. (2011) · Endocrinology · doi:10.1210/en.2011-1143 · Cited by 254
TAC3 and TACR3 Defects Cause Hypothalamic Congenital Hypogonadotropic Hypogonadism in Humans
Young, J., Bouligand, J., Francou, B., Raffin-Sanson, M.-L., Gaillez, S., Jeanpierre, M., Grynberg, M., Kamenicky, P., Chanson, P., Brailly-Tabard, S., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2600 · Cited by 249 · cited 1×
“Inactivating mutation of its gene or that encoding TACR3 cause delayed puberty or secondary hypogonadism (sHG) in adults [6].”
BackgroundTu, L. N., Morohaku, K., Manna, P. R., Pelton, S. H., Butler, W. R., Stocco, D. M., & Selvaraj, V. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.578286 · Cited by 239 · cited 1×
“However, Leydig cell-specific TSPO conditional knockout mice suggested that TSPO was not required for T production in vivo [115,116].”
BackgroundFactors affecting spermatogenesis upon gonadotropin-replacement therapy: A meta-analytic study
Rastrelli, G., Corona, G., Mannucci, E., & Maggi, M. (2014) · Andrology · doi:10.1111/andr.262 · Cited by 211
Self-citationBaker, B. Y., Lin, L., Kim, C. J., Raza, J., Smith, C. P., Miller, W. L., & Achermann, J. C. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1565 · Cited by 194 · cited 1×
“In humans, StAR mutations cause lipoid congenital adrenal hyperplasia that ranges from an almost complete inability to synthesize steroids [10], to less severe forms that retain partial StAR protein activity [11].”
BackgroundKisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men
George, J. T., Veldhuis, J. D., Roseweir, A. K., Newton, C. L., Faccenda, E., Millar, R. P., & Anderson, R. A. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0089 · Cited by 186 · cited 2×
“The native kisspeptin-54 and -10, acutely administered in healthy men, have been proven to elicit a strong stimulation of Gn secretion [34,35], and a continuous infusion of kisspeptin-10 for 22.”
BackgroundChua, M. E., Escusa, K. G., Luna, S., Tapia, L. C., Dofitas, B., & Morales, M. (2013) · Andrology · doi:10.1111/j.2047-2927.2013.00107.x · Cited by 183
Corona, G., Rastrelli, G., & Maggi, M. (2013) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2013.05.002 · Cited by 177 · cited 2×
“It is quite evident, however, that subjects complaining of sexual dysfunction represent a population overloaded with LOH with prevalence five to six times higher than that reported in the general population [29].”
BackgroundSelf-citationJannini, E. A., Screponi, E., Carosa, E., Pepe, M., Lo Giudice, F., Trimarchi, F., & Benvenga, S. (1999) · International Journal of Andrology · doi:10.1046/j.1365-2605.1999.00196.x · Cited by 146 · cited 2×
“showed that restoring erection by non-hormonal intervention (behavioural therapy, intracavernous injections) rescued an otherwise borderline low T level by 30 -- 40% of baseline values [126].”
BackgroundBoccardo, F., Rubagotti, A., Battaglia, M., Di Tonno, P., Selvaggi, F. P., Conti, G., Comeri, G., Bertaccini, A., Martorana, G., Galassi, P., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.12.013 · Cited by 145
Outcomes of clomiphene citrate treatment in young hypogonadal men
Katz, D. J., Nabulsi, O., Tal, R., & Mulhall, J. P. (2012) · BJU International · doi:10.1111/j.1464-410x.2011.10702.x · Cited by 142
Letrozole once a week normalizes serum testosterone in obesity-related male hypogonadism
Loves, S., Ruinemans-Koerts, J., & de Boer, H. (2008) · European Journal of Endocrinology · doi:10.1530/eje-07-0663 · Cited by 141
Guay, A. T., Jacobson, J., Perez, J. B., Hodge, M. B., & Velasquez, E. (2003) · International Journal of Impotence Research · doi:10.1038/sj.ijir.3900981 · Cited by 128
Liu, P. Y., Wishart, S. M., & Handelsman, D. J. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.7.8630 · Cited by 112
How to recognize late-onset hypogonadism in men with sexual dysfunction
Corona, G., Rastrelli, G., Vignozzi, L., Mannucci, E., & Maggi, M. (2012) · Asian Journal of Andrology · doi:10.1038/aja.2011.138 · Cited by 108 · cited 12×
“In addition, T and its precursor, D4 androstenedione, can be actively 10.1517/14656566.2015.993607 © 2015 Informa UK, Ltd. ISSN 1465-6566, e-ISSN 1744-7666 369 All rights reserved: reproduction in whole or in part not permitted transformed, through P450 aromatase, to other bioactive metabolites, such as estrone and 17…”
BackgroundResultInfluentialSelf-citationClomiphene citrate effects on testosterone/estrogen ratio in male hypogonadism
Shabsigh, A., Kang, Y., Shabsign, R., Gonzalez, M., Liberson, G., Fisch, H., & Goluboff, E. (2005) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2005.00075.x · Cited by 98
Emerging medication for the treatment of male hypogonadism
Corona, G., Rastrelli, G., Vignozzi, L., & Maggi, M. (2012) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2012.683411 · Cited by 93 · cited 11×
“In addition, T and its precursor, D4 androstenedione, can be actively 10.1517/14656566.2015.993607 © 2015 Informa UK, Ltd. ISSN 1465-6566, e-ISSN 1744-7666 369 All rights reserved: reproduction in whole or in part not permitted transformed, through P450 aromatase, to other bioactive metabolites, such as estrone and 17…”
BackgroundInfluentialSelf-citationSaltzstein, D., Sieber, P., Morris, T., & Gallo, J. (2005) · Prostate Cancer and Prostatic Diseases · doi:10.1038/sj.pcan.4500782 · Cited by 78
Kaminetsky, J., Werner, M., Fontenot, G., & Wiehle, R. D. (2013) · The Journal of Sexual Medicine · doi:10.1111/jsm.12116 · Cited by 78
Sildenafil increases serum testosterone levels by a direct action on the testes
Spitzer, M., Bhasin, S., Travison, T. G., Davda, M. N., Stroh, H., & Basaria, S. (2013) · Andrology · doi:10.1111/j.2047-2927.2013.00131.x · Cited by 67 · cited 2×
“In a recent large RCT, it was found that a 4-week run-in of PDE5 inhibitor (PDE5i), sildenafil, in hypogonadal men significantly raised T levels by a mean of 4 nmol/l [111], supporting a possible role of PDE5i as the sole treatment in selected men presenting with ED and mildly reduced T levels.”
BackgroundResultVeldhuis, J. D., Liu, P. Y., Keenan, D. M., & Takahashi, P. Y. (2012) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00450.2011 · Cited by 48 · cited 1×
“Although the efficacy of recombinant compounds in restoring T serum concentration has been proven [94,95], no studies, so far, have evaluated their effects on spermatogenesis.”
BackgroundLoves, S., de Jong, J., van Sorge, A., Telting, D., Tack, C. J., Hermus, A., Westerterp, K., & de Boer, H. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0190 · Cited by 45
Birzniece, V., Sata, A., Sutanto, S., & Ho, K. K. Y. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1477 · Cited by 22 · cited 1×
“However, due to an agonist activity in the liver they also increase sex hormone binding globulin (SHBG), therefore, the resulting fraction of unbound (free) T is often unchanged [49,52-55].”
Background
Cited by
Paediatric and adult-onset male hypogonadism
Salonia, A., Rastrelli, G., Hackett, G., Seminara, S. B., Huhtaniemi, I. T., Rey, R. A., Hellstrom, W. J. G., Palmert, M. R., Corona, G., Dohle, G. R., et al. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0087-y · Cited by 286
Self-citationCorona, G., Giagulli, V. A., Maseroli, E., Vignozzi, L., Aversa, A., Zitzmann, M., Saad, F., Mannucci, E., & Maggi, M. (2016) · Journal of Endocrinological Investigation · doi:10.1007/s40618-016-0480-2 · Cited by 185
Self-citationSalonia, A., Capogrosso, P., Boeri, L., Cocci, A., Corona, G., Dinkelman-Smit, M., Falcone, M., Jensen, C. F., Gül, M., Kalkanli, A., et al. (2025) · European Urology · doi:10.1016/j.eururo.2025.04.010 · Cited by 174
Self-citationTestosterone and Cardiovascular Risk: Meta-Analysis of Interventional Studies
Corona, G., Rastrelli, G., Di Pasquale, G., Sforza, A., Mannucci, E., & Maggi, M. (2018) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2018.04.641 · Cited by 138
Self-citationTreatment of Functional Hypogonadism Besides Pharmacological Substitution
Corona, G., Rastrelli, G., Morelli, A., Sarchielli, E., Cipriani, S., Vignozzi, L., & Maggi, M. (2020) · The World Journal of Men's Health · doi:10.5534/wjmh.190061 · Cited by 87
“It is important to note that several pharmacological treatments of either HG or ED are available and all are very efficacious, however, they are not the main topic of this review, as it has recently been covered elsewhere [2,21].”
BackgroundSelf-citation
Metadata
- Authors
- Corona, G., Ratrelli, G., & Maggi, M.
- Venue
- Expert Opinion on Pharmacotherapy
- Publisher
- Informa UK Limited
- Published
- 2014-12-19
- Volume
- 16
- Issue
- 3
- Pages
- 369-387
- ISSN
- 1465-6566 (ISSN-L)
- 1744-7666
- OpenAlex
- W2019781496
- Cited by
- 41
- References
- 40
- FWCI
- 3.35
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.